Childhood cancer trial aims to cut radiation without sacrificing cure
NCT ID NCT02684708
First seen Apr 21, 2026
Summary
This large international trial tested whether children and teens with classical Hodgkin lymphoma could be treated with less radiation therapy by adjusting their chemotherapy. Over 2,900 participants were randomly assigned to different chemotherapy schedules. The goal was to maintain the high cure rate while reducing long-term side effects from radiation. The study also tested a stronger chemotherapy regimen for intermediate and advanced stages to make up for the reduced radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHUV - Centre Hospitalier Universitaire Vaudois = LS, Départment femme - meré - enfant, Service de pédiatrie, Unité d'hématologie-oncologie pédiatrique
Lausanne, 1011, Switzerland
-
Clinic of Pediatric Oncology University Children's Hospital
Bratislava, 83340, Slovakia
-
Department of Medical Oncology Oslo University Hospital
Oslo, 0424, Norway
-
Department of Pediatric Hematology/Oncology (5054) The Child and Youth Clinic, University Hospital of Copenhagen
Copenhagen, 2100, Denmark
-
Dpt. of Pediatric Hematology and Oncology, Faculty Hospital Motol
Prague, 15006, Czechia
-
Head of Department of Pediatric Oncology and Hematology, Polish-American Pediatric Institute, Jagiellonian University Medical Faculty
Krakow, 30-663, Poland
-
Justus Liebig University of Giessen
Giessen, 35392, Germany
-
Our Lady's Children's Hospital, Crumlin
Dublin, 12, Ireland
-
Paediatric haemato-oncology, University Hospitals of Leuven
Leuven, 3000, Belgium
-
Pediatric Hematology & Oncology Children´s University Hospital
Uppsala, 75185, Sweden
-
Pediatric Radiotherapy and Youth Area Unit C.R.O. - Centro di Riferimento Oncologico IRCCS
Aviano, 33081, Italy
-
Princess Máxima Center for pediatric oncology
Utrecht, 3508, Netherlands
-
Royal Children's Hospital and Monash Medical Centre Royal Children's Hospital
Victoria Park, 3052, Australia
-
Sección de Onco-Hematología Pediátrica Hospital Universitario Virgen Macarena y Virgen del Rocío
Seville, 41071, Spain
-
Service d'Oncohématologie, Hopital d'Ènfants Armand Trousseau
Paris, 75571, France
-
St. Anna Kinderspital
Vienna, 1090, Austria
-
Starship Blood and Cancer Centre, Starship Children's Hospital
Auckland, 1142, New Zealand
-
Tel Aviv University Schneider Children's Medical Center of Israel The Rina Zaizov Pediatric Hematology Oncology Division
Petah Tikva, 49202, Israel
-
University College London Hospitals
London, NW1 2PG, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy drugs (cyclophosphamide, vincristine, prednisone, dacarbazine, etoposide, doxorubicin)
What this could lead to
If successful, this could lead to equally high cure rates for childhood Hodgkin lymphoma with fewer long-term side effects from radiation.
What could go wrong
This is a completed trial, so results are known but may not apply to all patients. Reducing radiotherapy might slightly increase relapse risk in some groups.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.